GELTEQ Secures $12M Funding and Launches SportsGel Brand
By ATTN Desk · Editorial oversight: Sean Han
GELTEQ LIMITED (GELS) Overview
GELTEQ LIMITED (NASDAQ: GELS) is a clinical-stage biotechnology company specializing in patented, ingestible gel-based delivery systems for pharmaceuticals, nutraceuticals, animal health, and sports performance products. The company’s proprietary gel platform—developed in collaboration with Monash University’s Medicines Manufacturing Innovation Centre—aims to improve absorption rates, reduce choking risks, and enable precise dosing for a variety of water-soluble and lipid-soluble compounds.
Corporate Structure and Leadership
- Headquarters: Melbourne, Australia
- Exchange: NASDAQ (Ticker: GELS)
- Employee Count: 2–10 (LinkedIn)
Executive Team
- Nathan J. Givoni, Co-Founder & Chief Executive Officer
- Simon Szewach, Executive Chairman
- Dr. Paul Wynne, Chief Scientific Officer (appointed May 2025)
- Matthew Jones, Head of Sports Performance (appointed May 2025)
Research & Collaboration
- Monash University MMIC: Full-time R&D partner for formulation, testing, and scale-up
- Academic & Commercial Partners: GSK, Roche, Pfizer (via Monash relationships)
Key Developments in 2025
- March 14, 2025 – Secured a funding agreement with Lincoln Park Capital Fund, LLC for up to US $12 million of ordinary shares over 24 months.
- April 2025 – Announced a three-year sponsorship of the Professional Pickleball Tour of Australia and the Major League Pickleball of Australia & New Zealand, granting exclusivity for consumable performance gels under the Sportsgel brand.
- April 2025 – Launched the SportsGel brand and entered a distribution agreement with WPIC Marketing + Technologies for Asia-Pacific markets; first roll-out scheduled in China during H1 2025.
- May 2025 – Appointed Matthew Jones, an international sports dietitian with over 12 years of experience in elite sports, as Head of Sports Performance.
- May 2025 – Appointed Dr. Paul Wynne, former manager of Monash’s Medicines Manufacturing Innovation Centre, as Chief Scientific Officer.
- June 2025 – Received FDA approval for a suitability petition enabling an accelerated abbreviated New Animal Drug Application (ANADA) pathway.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-06-10 close) | US $2.2492 (+32.31%) |
| Volume (2025-06-10) | 9,378,772 |
| 52-Week Range | US $0.77 – US $5.50 |
| Market Capitalization | US $16.0 million |
| Revenue (TTM) | US $143,310 |
| Net Income (TTM) | –US $3.55 million |
| Diluted EPS (TTM) | –US $0.24 |
| Total Cash (MRQ) | US $24,520 |
| Total Debt/Equity (MRQ) | 25.43% |
| Levered Free Cash Flow (TTM) | –US $293,770 |
| Return on Assets (TTM) | –8.04% |
| Return on Equity (TTM) | –21.00% |
- Capital Raise: The Lincoln Park facility provides liquidity to fund R&D, marketing, and working capital while capping dilution (no more than 19.99% of outstanding shares without shareholder approval).
- Profitability: The company reports low revenue and recurring net losses, reflecting investments in clinical development and commercialization efforts.
- Balance Sheet: The cash position relative to the burn rate indicates the importance of the committed equity facility.
- Liquidity: Average daily volume of approximately 1.55 million shares; May 2025 volumes increased following strategic announcements.
Market Position and Industry Context
- Oral Delivery Innovation: Gel-based systems address challenges in drug and nutrient delivery, including bioavailability and precise dosing.
- Pharmaceutical & Nutraceutical Sectors: Collaborations with academic and commercial laboratories support product pipelines for both human and animal health.
- Sports Nutrition: Entry into a US $6.5 billion Asia-Pacific sports nutrition market (2022 data) via SportsGel, which focuses on running, cycling, and hydration formulations.
- Animal Health: FDA ANADA pathway approval facilitates market entry for veterinary gel products.
- Competitive Landscape: Companies developing novel dosage forms—such as gummies and oral dissolvables—represent adjacent technologies, while Gelteq’s gel matrix technology is designed for distinct functional advantages.
tl;dr
As of June 10, 2025, GELS shares increased by 32.31% to US $2.2492 on elevated trading volume supported by:
- A US $12 million equity purchase commitment from Lincoln Park (March 2025)
- Three-year Sportsgel sponsorship of professional pickleball leagues (April 2025)
- H1 2025 China launch of SportsGel with WPIC distribution
- May 2025 appointments of Matthew Jones (Head of Sports Performance) and Dr. Paul Wynne (CSO)
- FDA ANADA pathway approval for animal drug products
The funding facility and strategic partnerships are aimed at supporting clinical and commercial initiatives across pharmaceutical, sports nutrition, and animal health sectors throughout 2025 and beyond.